Search results
Your search for process/pmg6 returned no results
Showing 376 to 390 of 2854 results for process
Showing 376 to 390 of 2854 results for process
This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.
NICE is unable to make a recommendation about the use in the NHS of toripalimab (Loqtorzi) with chemotherapy for untreated advanced oesophageal squamous cell cancer in adults. This is because Shanghai Junshi Bioscience has requested a delay to the evidence submission.
Show all sections
Sections for TA1024
NICE is unable to make a recommendation on sacituzumab govitecan (Trodelvy) for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1089
NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1112
NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer. This is because Roche did not provide an evidence submission.
Show all sections
Sections for TA560
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma in adults. This is because Merck Sharpe & Dohme will not be proceeding with the evidence submission for the appraisal.
Show all sections
Sections for TA1125
This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.
View quality statements for QS22Show all sections
Sections for QS22
- Quality statements
- Quality statement 1: Access to antenatal care
- Quality statement 2: Risk assessment
- Quality statement 3: Continuity of carer
- Quality statement 4: Vaccination
- Quality statement 5: Referral for stop-smoking support and treatment
- Quality statement 6: Healthy eating in pregnancy
- Update information
This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.
View quality statements for QS37Show all sections
Sections for QS37
- Quality statements
- Quality statement 1: Communication between healthcare professionals at transfer of care
- Quality statement 2: Information and advice about babies' feeding
- Quality statement 3: Symptoms and signs of illness in babies
- Quality statement 4: Face-to-face feeding support
- Quality statement 5: Safer practices for bed sharing
- Quality statement 6: GP postnatal check for women
- Quality statement 7: Advice on introducing solid food
NICE is unable to make a recommendation on ramucirumab (Cyramza) with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer. This is because Eli Lilly and Company Limited did not provide an evidence submission.
Show all sections
Sections for TA635
NICE is unable to make a recommendation on ruxolitinib (Jakavi) for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1132
NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
Show all sections
Sections for TA1032
This quality standard covers care and support and services for children, young people and adults with a learning disability (or a learning disability and autism) and behaviour that challenges, and their families and carers. It describes high quality care in priority areas for improvement.
View quality statements for QS101Show all sections
Sections for QS101
- Quality statements
- Quality statement 1: Lead commissioner
- Quality statement 2: Annual health check
- Quality statement 3: Initial assessment of behaviour that challenges
- Quality statement 4: Named lead practitioner
- Quality statement 5: Involving families and carers
- Quality statement 6: Parent-training programmes
- Quality statement 7: Personalised daily activities
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. This is because Merck Sharp & Dohme UK Ltd did not provide an evidence submission
Show all sections
Sections for TA570
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA1047
NICE is unable to make a recommendation about the use in the NHS of ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over. This is because Novartis has confirmed that it does not intend to make an evidence submission for the appraisal.
Show all sections
Sections for TA840